For a patient on insulin glargine (Lantus) 10 units whose blood glucose has dropped to the low 70 mg/dL after three 25‑mL boluses of D‑50% dextrose and is now receiving D‑10% dextrose at 10 mL/hr, how much should the Lantus dose be reduced?

Reduce Lantus by 20–30% Immediately and Monitor Closely

For a patient on Lantus 10 units whose blood glucose has dropped to 69–73 mg/dL after three 25‑mL boluses of D‑50% dextrose and is now receiving D‑10% at 10 mL/hr, reduce the Lantus dose by 2–3 units (to 7–8 units) before the next scheduled administration. This represents a 20–30% reduction, which is the standard guideline‑recommended response to any unexplained hypoglycemia (glucose < 70 mg/dL) in patients receiving basal insulin 1, 2.

---

Immediate Dose‑Reduction Protocol

• Reduce Lantus by 10–20% (1–2 units) as the minimum intervention if a single hypoglycemic episode occurs without an obvious precipitating cause 1, 2.
• Reduce Lantus by 20–30% (2–3 units) when hypoglycemia is recurrent or when the patient requires IV dextrose boluses and continuous dextrose infusion, as this signals profound over‑insulinization 1, 2.
• The American Diabetes Association explicitly states that any glucose < 70 mg/dL mandates an immediate 10–20% dose reduction before the next insulin administration, and more aggressive reductions (up to 30%) are warranted when hypoglycemia is severe or requires IV dextrose 1, 2.

---

Rationale for 20–30% Reduction in This Clinical Scenario

• Three D‑50% boluses (75 g total dextrose) plus continuous D‑10% infusion indicate severe, refractory hypoglycemia that cannot be corrected with standard oral carbohydrate treatment 2.
• The need for sustained IV dextrose (D‑10% at 10 mL/hr delivers 1 g dextrose/hour) demonstrates ongoing insulin excess despite aggressive glucose replacement 2.
• Hospitalized patients receiving basal insulin experience nocturnal hypoglycemia in 78% of cases, yet 75% receive no dose adjustment before the next administration—a common and dangerous management gap that must be avoided 1.
• Failure to reduce the basal dose promptly perpetuates the hypoglycemia cycle and increases the risk of severe neuroglycopenic events 1, 2.

---

Monitoring Requirements After Dose Reduction

• Check capillary glucose every 4–6 hours for the first 24–48 hours after reducing Lantus to detect rebound hyperglycemia or persistent hypoglycemia 1, 2.
• Measure fasting glucose daily to guide further basal insulin adjustments; if fasting glucose rises above 180 mg/dL after dose reduction, increase Lantus by 2 units every 3 days until fasting glucose returns to the target range of 80–130 mg/dL 1.
• Continue D‑10% infusion at 10 mL/hr until the patient can tolerate oral intake and glucose stabilizes above 100 mg/dL without further dextrose support 2.
• If glucose remains < 70 mg/dL despite the 20–30% Lantus reduction and continuous D‑10%, consider an additional 10–20% reduction (total 30–50% from baseline) and investigate other causes of hypoglycemia (e.g., renal impairment, sepsis, adrenal insufficiency) 1, 2.

---

Titration Protocol After Stabilization

• Once glucose stabilizes above 100 mg/dL and oral intake resumes, discontinue D‑10% and reassess the Lantus dose over the next 3–7 days 2.
• If fasting glucose remains 80–130 mg/dL on the reduced dose (7–8 units), maintain this dose and monitor for 1 week before considering further adjustments 1.
• If fasting glucose rises to 140–179 mg/dL, increase Lantus by 2 units every 3 days 1.
• If fasting glucose rises to ≥180 mg/dL, increase Lantus by 4 units every 3 days 1.
• Target fasting glucose: 80–130 mg/dL 1.

---

Common Pitfalls to Avoid

• Do not delay the dose reduction after a hypoglycemic event requiring IV dextrose; studies show that 75% of hospitalized patients with hypoglycemia receive no basal insulin adjustment before the next dose, perpetuating the problem 1.
• Do not rely solely on correction insulin or continued dextrose infusion without adjusting the scheduled basal dose; this reactive approach is unsafe and fails to address the underlying over‑insulinization 1, 2.
• Never discontinue Lantus entirely in type 1 diabetes or insulin‑dependent type 2 diabetes, even when hypoglycemia occurs, to avoid precipitating diabetic ketoacidosis 1.
• Do not assume the original 10‑unit dose was appropriate; the hypoglycemia indicates the dose was too high for this patient's current insulin sensitivity, and a lower maintenance dose (7–8 units) may be optimal long‑term 1.

---

Alternative Basal Insulin Timing (If Hypoglycemia Persists)

• If early‑morning or nocturnal hypoglycemia recurs despite dose reduction, consider administering Lantus in the morning rather than the evening to shift insulin activity away from the overnight period 1.
• Morning administration can reduce the risk of early‑morning hypoglycemia by aligning peak basal coverage with daytime meals and activity 1.

---

Expected Clinical Outcomes

• After a 20–30% basal dose reduction (to 7–8 units), fasting glucose should stabilize within 80–130 mg/dL in 3–7 days without further hypoglycemic episodes 1.
• If hyperglycemia persists, titrate the basal dose upward by 2 units every 3 days until the fasting target is achieved 1.
• Properly adjusted basal insulin provides consistent 24‑hour coverage without causing nocturnal hypoglycemia or early‑morning hyperglycemia 1.

---

High‑Risk Patient Considerations

• Elderly patients (>65 years), those with renal impairment (eGFR < 45 mL/min), or patients with poor oral intake require lower basal insulin doses (0.1–0.25 units/kg/day) to minimize hypoglycemia risk 1.
• For patients with CKD stage 5, reduce total daily insulin by 50% for type 2 diabetes and by 35–40% for type 1 diabetes 1.
• In hospitalized patients on high‑dose home insulin (≥0.6 units/kg/day), reduce the total daily dose by 20% upon admission to prevent inpatient hypoglycemia 1.

---

Hypoglycemia Treatment Protocol

• Treat any glucose < 70 mg/dL promptly with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck after 15 minutes, and repeat if needed 1, 2.
• For severe hypoglycemia with altered mental status or inability to take oral glucose, administer 10–20 g of IV dextrose (D‑50%) and recheck glucose in 15 minutes 2.
• If hypoglycemia persists despite treatment, start D‑10% infusion at 50 mL/hr (5 g dextrose/hour) to maintain glucose above 100 mg/dL while reducing basal insulin 2.